Don't know what happened to my post? Here it is again.The 2013 NewsMakers are outpacing the biotech bull market. The aggregate market cap of the NewsMakers companies has jumped this year from $23.6 billion to $39.8 billion through August. This is a 69% increase, compared with a 48% gain in the BioCentury 100 Index and a 53% gain in the NASDAQ Biotechnology Index (NBI). Investors also have poured more than $4.7 billion into the Class of 2013 since the beginning of 2012, including nearly $2.5 billion this year.
"Biotech is in the midst of a record 5 year run, outpacing the key equity indices, including the Dow Jones Industrials, the S&P 500 and the NASDAQ Biotechnology Index," said BioCentury Publisher Eric Pierce. "Members of the NewsMakers Class of 2013 have played a significant role in drawing investors into the biotech space. We're pleased to have the opportunity to showcase them and their upcoming, near-term milestones to the investment community at NewsMakers."
The NewsMakers pipeline is robust with both partnered and unpartnered programs that should be of interest to pharma business development and licensing professionals. The group has more than 50 products on the market, and nine compounds under regulatory review, including three with near-term PDUFA dates. The group is conducting more than 250 clinical trials, including 35 Phase III trials and more than 140 Phase II trials across key disease areas including cancer, infectious diseases, inflammation, cardiovascular and autoimmune disorders. The NewsMakers assets include more than 225 unpartnered programs, with more than 140 of them in the clinic and 70 in preclinical/IND stages.